DSP 9599
Alternative Names: DSP9599Latest Information Update: 05 Nov 2023
At a glance
- Originator Dainippon Sumitomo Pharma
- Class
- Mechanism of Action Renin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 14 Jun 2013 Pharmacokinetics, adverse events & pharmacodynamics data from a phase I trial in Healthy volunteers presented at the 23rd European Meeting on Hypertension (ESH-2013)
- 31 Jan 2013 Discontinued - Phase-I for Hypertension in Japan (PO)
- 31 Mar 2012 Phase-I clinical trials in Hypertension in Japan (PO)